Establishment of ATP-Based Luciferase Viability Assay in 96-Well Plate for Trypanosoma congoense

Keisuke SUGANUMA1)**, Puttick ALLAMANDA1,2)**, Hassan HAKIM1-3), Mo ZHOU1), Jose Ma. ANGELES1), Shin-ichiro KAWAZU1) and Noboru INOUE1)**

1)National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada, Obihiro, Hokkaido 080–8555, Japan
2)Disease Investigation Center (DIC) Subang, West Java 41212, Indonesia
3)Department of Protozoology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Sakamoto, Nagasaki 852–8523, Japan

(Received 28 May 2014/Accepted 3 July 2014/Published online in J-STAGE 23 July 2014)

ABSTRACT. Animal African trypanosomosis (AAT), caused by Trypanosoma congoense, is widespread throughout sub-Saharan Africa. There are significant concerns related to the current drugs available for the treatment of AAT due to their limited effectiveness across species and their adverse effects. Moreover, drug resistant trypanosomes have recently been reported in the field. High throughput screening (HTS) of large chemical compound library collections is a promising approach for identifying novel drug candidates. While HTS for Trypanozoon trypanosomes, *T. brucei* ssp. and *T. evansi* is well established, no assays have been developed for *T. congoense*. In the present study, the authors developed an ATP-based luciferase viability assay for *T. congoense* in a 96-well plate format. The calculated 50% inhibitory concentration (IC₅₀) values for pentamidine and diminazene were 10–100 times higher in *T. congoense* than in *T. brucei*. This result suggests that the transporters for the 2 tested compounds differ between *T. congoense* and *T. brucei*. This assay could further be applied to screen novel chemical compounds for the treatment of AAT caused by *T. congoense*.

KEY WORDS: Animal African trypanosomosis, drug screening, luciferase assay, Trypanosoma congoense

doi: 10.1292/jvms.14-0273; J. Vet. Med. Sci. 76(11): 1437–1441, 2014

Animal African trypanosomosis (AAT) in domesticated and wild animals, known as Nagana, is mainly caused by *Trypanosoma congoense*, *T. vivax* and *T. brucei brucei* [9]. The most consistent clinical features of Nagana in livestock are intermittent fever and anemia, although general leukopenia, splenomegaly and hepatomegaly, and weight loss are also present in some cases. *T. congoense* and *T. vivax* only proliferate in blood circulation, whereas *T. b. brucei* has also been found to infect the central nervous system [2, 14, 16, 21]. The FAO estimates that AAT causes a combined economic loss of agricultural gross domestic product of US$ 4.75 billion per year (http://www.fao.org/ag/againfo/programmes/en/paat/disease.html). Currently, 3 drugs are commercially available for the treatment of AAT, namely: diminazene, isometadim and homidium. The latter 2 drugs can also be used for chemoprophylaxis [9]. In the case of human African trypanosomosis (HAT) treatment, pentamidine and suramine are the first choice of drugs for the treatment of *T. b. rhodesiense* and *T. b. gambiense*, respectively [2]. However, drug resistant trypanosomes and drug refractory trypanosomosis have been reported from the field for both HAT and AAT [1, 6, 7, 19]. Novel trypanocidal compounds are therefore needed for the treatment of drug resistant trypanosomosis.

High throughput screening (HTS) assay of large compound libraries has been undertaken to discover novel therapeutic candidates for several parasites [18]. This has been performed for a number of parasitic diseases, such as American trypanosomosis (Chagas’ disease), leishmaniosis and malaria [8, 13, 22, 25]. The HTS approach has been proven to have the potential to identify new drugs with novel modes of action. HTS approaches with specific targets have been well established and reported for *Trypanozoon* trypanosomes, *T. b. brucei*, *T. b. gambiense*, *T. b. rhodesiense* and *T. evansi* [10, 20, 23, 24, 26]. A viability assay, utilizing Alamar Blue™ dye, has been developed for all *T. brucei* ssp. [20, 23]. However, the Alamar Blue™ dye assay has some problems in that it is time-consuming to perform and its sensitivity is low. Recently, a luciferase viability assay for measuring the ATP concentration of cells was adapted to HTS to evaluate viable *T. b. brucei* and *T. b. gambiense* cell numbers [24, 26]. In comparison, the luciferase assay method offers greater sensitivity and is less time-consuming than the Alamar Blue™ assay system [23, 24]. This assay could therefore be used in HTS for important animal parasites, such as *T. congoense*. However, no HTS assay for *T. congoense* has previously been developed or reported.

In the present study, we initially established an ATP-based luciferase viability assay for *T. congoense* using the 2 available drugs against trypanosomosis: diminazene and pentamidine. We applied this assay in evaluating ATP congruent cell numbers [24, 26]. In comparison, the luciferase assay has some problems in that it is time-consuming to perform and its sensitivity is low. Therefore, a luciferase assay for measuring the ATP concentration of cells was adapted to HTS to evaluate viable *T. b. brucei* and *T. b. gambiense* cell numbers [24, 26]. In comparison, the luciferase assay method offers greater sensitivity and is less time-consuming than the Alamar Blue™ assay system [23, 24]. This assay could therefore be used in HTS for important animal parasites, such as *T. congoense*. However, no HTS assay for *T. congoense* has previously been developed or reported.

In the present study, we initially established an ATP-based luciferase viability assay for *T. congoense* using the 2 available drugs against trypanosomosis: diminazene and pentamidine. We applied this assay in evaluating ATP congruent to the *T. congoense* cell number in culture to develop an HTS system for this trypanosome.
MATERIALS AND METHODS

Parasites and in vitro culture: Trypanosoma Trypanosoma congolense IL3000, a savannah type strain isolated near the Kenya/Tanzania border in 1966, was used in this study. The blood stream form (BSF) of T. congolense IL3000 was propagated at 33°C in air using Hirum’s modified Iscove’s medium (HMI)-9 composed of Iscove’s modified Dulbecco’s medium (Sigma-Aldrich, Tokyo, Japan) supplemented with 20% heat inactivated-fetal bovine serum (HI-FBS), 60 mM HEPES (Sigma-Aldrich), 1 mM pyruvic acid sodium salt, 0.0001% 2-β-mercaptoethanol (Sigma-Aldrich), 0.4 g/l transferrin and 6.7 ng/l sodium selenite (ITS-X: Invitrogen), 0.0001% 2-β-mercaptoethanol (Sigma-Aldrich), 0.4 g/l BSA (Sigma-Aldrich) and 2 mM L-cysteine (Sigma-Aldrich), as previously reported [12]. The BSF cultures were maintained by replacing the entire culture supernatant with fresh medium every other day.

Optimization of cell density and calculation of doubling time: A growth curve was plotted to estimate the maximum number of cells and calculate the doubling time. One hundred µl of T. congolense (at a density of 1 × 10⁵, 5 × 10⁴ and 2.5 × 10⁴ cells/ml) was incubated in a 96-well plate at 33°C. Trypanosomes were counted every 24 hr post-inoculation until day 6 using a counting chamber after appropriate dilution by phosphate buffered saline with glucose (PSG).

Dilution time (Td) was calculated by counting the cells in the 1-log phase of growth and using the equation: Td=(t₂−t₁) × log (2)/log (q₂/q₁). Two measurements were made: the initial count (q₁) at time (t₁) and the resultant density following 24 hr incubation (q₂, t₂) [23, 24].

Optimization of dimethylsulfoxide concentration: Fifty µl of different concentrations of dimethylsulfoxide (DMSO; Wako Pure Chemical Industries, Ltd., Osaka, Japan) diluted in HMI-9 medium were added into a 96-well plate containing 50 µl of T. congolense at a density of 2 × 10⁴ cells/ml. The plate was incubated for a further 72 hr, and the inhibition rate was calculated. The optimized luciferase assay protocol was then performed (see next section).

Finally optimized HTS assay conditions: After optimization, the final conditions for the assay were established for conducting the tests. Fifty µl of various concentrations of reference compounds in HMI-9 with 0.5% DMSO were added to a Nunc® MicroWell 96-well optical bottom plate (Thermo Fisher Scientific K.K., Yokohama, Japan) containing 50 µl of T. congolense at a density of 2 × 10⁵ cells/ml. The final concentration of the parasite cell used in the assay was 1 × 10⁴ cells/ml, and the DMSO was at a final concentration of 0.25% in 100 µl of HMI-9 per well. The cells were incubated for 72 hr, and subsequently, 50 µl of CellTiter-Glo™ Luminescent Cell Viability Assay reagent (Promega Japan, Tokyo, Japan) was added to evaluate intracellular ATP concentration. The plate was shaken for 500 shakes/ min by MS3 basic plate shaker (IKA®, JAPAN K.K., Osaka, Japan) in 2 min to facilitate cell lysis and release intracellular ATP, and then incubated for another 10 min at room temperature. The plate was read using a GloMax®-Multi+ Detection System plate reader (Promega Japan).

Statistical analysis of samples: The quality of this assay was evaluated by Z’-factor [28] with the following formula: Z’-factor =1−{(3×SD A + 3×SD B)/(mean A − mean B)}; where A=the mean signal of each assay (cell growth detected in wells containing T. congolense in HMI-9 without compounds) and B=the signal of 500 ng/ml of reference compounds to the cells to cause 100% culture death. The coefficient of the determination value (R²) was calculated using GraphPad PRISM 5 (GraphPad Software Inc., CA, U.S.A.).

Determination of reference compounds 50% inhibitory concentration (IC₅₀): Diminazene aceturate (Sigma-Aldrich) and pentamidine (Sigma-Aldrich) were used for estimating drug sensitivity in this assay. Both compounds were stored as 10 mg/ml stock solutions in DMSO. Two-fold drug dilutions were made in triplicate from 500–1.95 ng/ml in HMI-9 with 0.5% DMSO. The IC₅₀ value of each reference compound was calculated by plotting the% inhibition (0% inhibition=the luminescence of trypanosome culture well without any chemicals) against log in GraphPad PRISM 5 software (GraphPad Software Inc.).

RESULTS

Establishment of HTS assay: For establishment of ATP-based luciferase viability assay for HTS in T. congolense, the maximum cell concentration linearly correlated with luminescence was used to optimize the test. The luminescence signal was well correlated, in a linear fashion, with trypanosome cell concentrations of up to 1 × 10⁶ cells/ml in 100 µl per well (R²=0.99) (Fig. 1A). However, this linear correlation was not seen when a higher concentration was used (Data not shown). The condition of the cell culture that leads to a final concentration of 1 × 10⁶ cells/ml in day 3 was optimized using different concentrations as shown in Fig. 1B. In our in vitro study, a start of 1 × 10⁵ cells/ml culture reached nearly 1 × 10⁶ cells/ml after 72 hr incubation (Fig. 1B). This condition was therefore utilized in the present study. Finally, the DMSO concentration needed for the assay was optimized by testing the effect of 0–4% DMSO on trypanosome growth. The results showed that 4% DMSO completely inhibited cell proliferation, whereas concentrations of ≤0.25% inhibited cell proliferation by <20% (Fig. 1C). In addition, using the information on the T. congolense culture day 1 to day 5 log phase proliferation, the doubling time was calculated to be 15 ± 2 hr (Fig. 1B). HMI-9 containing 0.25% DMSO was therefore utilized for the chemical compound dilution.

Evaluation of the HTS assay: To evaluate the established assay system, the authors initially evaluated pentamidine and diminazene aceturate, calculating its IC₅₀ values (Fig. 2). The IC₅₀ values of pentamidine and diminazene were calculated as 100.45 ± 26.08 ng/ml (169.48 ± 44.00 nM) and 55.98 ± 13.15 ng/ml (108.65 ± 25.25 nM), respectively (Table 1). In addition, the Z’-factor values of pentamidine and diminazene were calculated as 0.86 ± 0.06 and 0.94 ± 0.03, respectively (Table 1). These 2 compounds were also tested against...
LUCIFERASE BASED HTS FOR T. CONGOLENSE

The IC₅₀ values of pentamidine and diminazene in T. b. brucei were 0.64 ± 0.30 ng/ml (1.09 ± 0.50 nM) and 6.75 ± 0.40 ng/ml (13.09 ± 2.94 nM), respectively (Supplemental Table 1). In addition, those of T. evansi were 0.68 ± 0.40 ng/ml (1.15 ± 0.67 nM) and 8.15 ± 2.84 ng/ml (13.09 ± 2.94 nM), respectively (Supplemental Table 1). The results showed that the IC₅₀ values of these compounds for T. b. brucei and T. evansi were 6–100 times lower than those of T. congolense.

DISCUSSION

In this study, the authors established and evaluated the ATP-based luciferase viability assay in 96-well plate for T. congolense. Because of the intracellular ATP levels detected in viable cells, the luminescence levels and the numbers of trypanosomes were directly proportional (Fig. 1A). To optimize the cell culture with a final concentration of 1 × 10⁶ cells/ml on day 3, T. congolense was cultivated with different starting concentrations in 96-well plate (Fig. 1B). The concentration of T. congolense on day 1 was shown lower than that on day 0 (Fig. 1B). T. congolense BSF proliferates in a cell adhesion dependent manner at the vascular endothelium in vivo or at the bottom of the culture flask in vitro [11, 12]. Therefore, BSF that failed to adhere will eventually die on the first day of culture, resulting in a lower number of trypanosomes on day 1 than on day 0. To evaluate this assay, the Z’-factor was calculated. The Z’-factor values of pentamidine and diminazene for T. congolense were calculated as 0.86 ± 0.06 and 0.94 ± 0.03, respectively (Table 1). In addition, the Z’-factors for T. b. brucei and T. evansi were also >0.5 (Supplemental Table 1). These results suggested that the assay system could be applied to the HTS system for trypanosome, since it showed a remarkable Z’-factor value of 1> Z’-factor ≥0.5 [28].

Previous reports showed that the IC₅₀ values of pentamidine and diminazene for T. b. brucei and T. evansi were
Fig. 2. The IC₅₀ values of pentamidine and diminazene for *T. congolense*. The IC₅₀ values of diminazene and pentamidine were evaluated for *T. congolense* using the ATP-based luciferase viability assay. The percentage of inhibition was relative to that of the control well (where no chemical compounds were added). The sigmoidal dose response curve graphs were plotted by GraphPad PRISM5 software.

2–100 times lower than our results with *T. congolense* [10, 20, 23, 24, 26]. These results suggest that pentamidine and diminazene transporter of *T. congolense* could differ to that of the *T. brucei*. It was previously reported that *T. brucei* adenosine transporter 1 (TbAT1), identified as a P2 type aminopurine transporter of *T. brucei*, is responsible for the diminazene and pentamidine uptake [17]. The orthologue aminopurine transporter of *T. brucei* adenosine transporter 1 (TbAT1), identified as a P2 type orthologous gene has recently been identified in *T. congolense* and was named as *T. congolense* adenosine transporter 1 (TcoAT1) [5]. However, sequencing analysis suggested that TcoAT1 was not a true orthologous gene of P2-type purine transporter, TbAT1, but rather that it seemed to be an orthologous gene of P1-type purine transporter, TbNT10 [17]. In addition, it was reported that the IC₅₀ value of pentamidine and diminazene became >200 μM when TcoAT1 was over-expressed in diminazene resistant *T. b. brucei* (B48 strain) [17]. The IC₅₀ values of *T. congolense* in our study were more than 1,000 times lower than in the aforementioned report, suggesting that in *T. congolense*, pentamidine and diminazene uptake likely occurs via an unknown aminopurine transporter.

HTS systems are very well established for HAT and leishmaniosis, where they are utilized for screening chemical compound libraries to facilitate the development of therapeutic medicine. In the case of *T. congolense*, which causes a neglected tropical parasitic animal disease, this report is useful for the development of a more sensitive assay, which is necessary for establishing HTS. This will therefore offer a great advantage and be an efficient tool for screening and determining novel animal trypanocidal drugs in future studies.

|          | Pentamidine | Diminazene |
|----------|-------------|------------|
| IC₅₀ (ng/ml) | 100.45 ± 26.08 | 55.98 ± 13.15 |
| IC₅₀ (nM) | 169.48 ± 44.00 | 108.65 ± 25.51 |
| Z’-factor | 0.86 ± 0.06 | 0.94 ± 0.03 |
| R²        | 0.98 ± 0.02 | 0.99 ± 0.01 |

All values were calculated from 6 independent experiments and shown as the mean value ± standard deviation. IC₅₀: 50% inhibitory concentration, R²: coefficient of determination.

ACKNOWLEDGMENTS. This study was financially supported by the Japan Society for the Promotion of Science (JSPS), Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), the Japan International Cooperation Agency (JICA) and the JST/JICA, SATREPS.

REFERENCES
1. Baker, N., de Koning, H. P., Mäser, P. and Horn, D. 2013. Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story. Trends Parasitol. 29: 110–118. [Medline] [CrossRef]
2. Barrett, M. P., Burchmore, R. J., Stich, A., Lazzari, J. O., Frasch, A. C., Cazzulo, J. J. and Krishna, S. 2003. The trypanosomiases. Lancet 362: 1469–1480. [Medline] [CrossRef]
3. Barrett, M. P., Zhang, Z. Q., Denise, H., Giroud, C. and Baltz, T. 1995. A diamidine-resistant *Trypanosoma equiperdum* clone contains a P2 purine transporter with reduced substrate affinity. Mol. Biochem. Parasitol. 73: 223–229. [Medline] [CrossRef]
4. de Koning, H. P., Anderson, L. F., Stewart, M., Burchmore, R. J., Wallace, L. J. and Barrett, M. P. 2004. The trypanocide diminazene acetate is accumulated predominantly through the TbAT1 purine transporter: additional insights on diamidine resistance in african trypanosomiasis. Antimicrob. Agents Chemother. 48: 1515–1519. [Medline] [CrossRef]
5. Delespaux, V., Chitanga, S., Geyseren, D., Goethals, A., van den Bossche, P. and Geerts, S. 2006. SSCP analysis of the P2 purine transporter TcoAT1 gene of *Trypanosoma congolense* leads to a simple PCR-RFLP test allowing the rapid identification of diminazene resistant stocks. Acta Trop. 100: 96–102. [Medline] [CrossRef]
6. Delespaux, V., Dinka, H., Masumu, J., Van den Bossche, P. and Geerts, S. 2008. Five-fold increase in *Trypanosoma congolense* isolates resistant to diminazene acetate over a seven-year period in Eastern Zambia. Drug Resist. Updat. 11: 205–209. [Medline] [CrossRef]
7. Delespaux, V., Geyseren, D., Van den Bossche, P. and Geerts, S. 2008. Molecular tools for the rapid detection of drug resistance in animal trypanosomiasis. Trends Parasitol. 24: 236–242. [Medline] [CrossRef]
8. Engel, J. C., Ang, K. K., Chen, S., Arkin, M. R., McKerrow, J. H. and Doyle, P. S. 2010. Image-based high-throughput drug screening targeting the intracellular stage of *Trypanosoma cruzi*, the agent of Chagas’ disease. Antimicrob. Agents Chemother. 54: 3326–3334. [Medline] [CrossRef]
9. Geerts, S., Holmes, P. H., Eijsler, M. C. and Diall, O. 2001. African bovine trypanosomiasis: the problem of drug resistance. Trends Parasitol. 17: 25–28. [Medline] [CrossRef]
10. Gillingwater, K., Buscher, P. and Brun, R. 2007. Establishment of a panel of reference Trypanosoma evansi and Trypanosoma equiperdum strains for drug screening. Vet. Parasitol. 148: 114–121. [Medline] [CrossRef]

11. Hemphill, A. and Ross, C. A. 1995. Flagellum-mediated adhesion of Trypanosoma congoense to bovine aorta endothelial cells. Parasitol. Res. 81: 412–420. [Medline] [CrossRef]

12. Hirumi, H. and Hirumi, K. 1991. In vitro cultivation of Trypanosoma congolense bloodstream forms in the absence of feeder cell layers. Parasitology 102: 225–236. [Medline] [CrossRef]

13. Lang, T., Goyard, S., Lebastard, M. and Milon, G. 2005. Bioluminescent Leishmania expressing luciferase for rapid and high-throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice. Cell. Microbiol. 7: 383–392. [Medline] [CrossRef]

14. MacLean, L., Myburgh, E., Rodgers, J. and Price, H. P. 2013. Imaging African trypanosomes. Parasite Immunol. 35: 283–294. [Medline] [CrossRef]

15. Matovu, E., Stewart, M. L., Geiser, F., Brun, R., Mäser, P., Wallace, L. J., Enyaru, J. C., Barrett, M. P., Kaminsky, R., Seebeck, T. and de Koning, H. P. 2003. Mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei. Eukaryot. Cell 2: 1003–1008. [Medline] [CrossRef]

16. Mulenga, C., Mhlanga, J. D., Kristensson, K. and Robertson, B. 2001. Trypanosoma brucei brucei crosses the blood-brain barrier while tight junction proteins are preserved in a rat chronic disease model. Neuropathol. Appl. Neurobiol. 27: 77–85. [Medline] [CrossRef]

17. Munday, J. C., Rojas, López, K. E., Eze, A. A., Delespaux, V., Van Den Abbeele, J., Rowan, T., Barrett, M. P., Morrison, L. J. and de Koning, H. P. 2013. Functional expression of TcoAT1 reveals it to be a P1-type nucleoside transporter with no capacity for diminazene uptake. Int. J. Parasitol. Drugs Drug Resist. 3: 69–76. [Medline] [CrossRef]

18. Pécoul, B. 2004. New drugs for neglected diseases: from pipeline to patients. PLoS Med. 1: e6. [Medline] [CrossRef]

19. Pinder, M. and Authie, E. 1984. The appearance of isometamidium resistant Trypanosoma congolense in West Africa. Acta Trop. 41: 247–252. [Medline]

20. Rätz, B., Iten, M., Grether-Bühler, Y., Kaminsky, R. and Brun, R. 1997. The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T. b. rhodesiense and T. b. gambiense) in vitro. Acta Trop. 68: 139–147. [Medline] [CrossRef]

21. Rodgers, J., McCabe, C., Gettinby, G., Bradley, B., Condon, B. and Kennedy, P. G. 2011. Magnetic resonance imaging to assess blood-brain barrier damage in murine trypanosomiasis. Am. J. Trop. Med. Hyg. 84: 344–350. [Medline] [CrossRef]

22. Smilkstein, M., Sriwilaijaroen, N., Kelly, J. X., Wilairat, P. and Riscoe, M. 2004. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob. Agents Chemother. 48: 1803–1806. [Medline] [CrossRef]

23. Sykes, M. L. and Avery, V. M. 2009. Development of an Alamar Blue viability assay in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427. Am. J. Trop. Med. Hyg. 81: 665–674. [Medline] [CrossRef]

24. Sykes, M. L. and Avery, V. M. 2009. A luciferase based viability assay for ATP detection in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427. Parasit. Vectors 2: 54. [Medline] [CrossRef]

25. Tanaka, T. Q. and Williamson, K. C. 2011. A malaria gametocidal assay using oxidoreduction indicator, alamarBlue. Mol. Biochem. Parasitol. 177: 160–163. [Medline] [CrossRef]

26. Van Reet, N., Pyana, P., Rogé, S., Claes, F. and Büscher, P. 2013. Luminescent multiplex viability assay for Trypanosoma brucei gambiense. Parasit. Vectors 6: 207. [Medline] [CrossRef]

27. Witola, W. H., Inoue, N., Ohashi, K. and Onuma, M. 2004. RNA-interference silencing of the adenosine transporter-1 gene in Trypanosoma evansi confers resistance to diminazene aceturate. Exp. Parasitol. 107: 47–57. [Medline] [CrossRef]

28. Zhang, J. H., Chung, T. D. and Oldenburg, K. R. 1999. A simple statistical parameter for use in evaluation and validation of high-throughput screening assays. J. Biomol. Screen. 4: 67–73. [Medline] [CrossRef]